Clinical trial
Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS…
NCT00464087 · Medstar Health Research Institute, Other · Completed
Key facts
| NCT number | NCT00464087 |
|---|---|
| Title | Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI |
| Official title | Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III |
| Acronym | SWITCHIII |
| Lead sponsor | Medstar Health Research Institute, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Coronary Syndromes |
| Intervention type | Drug |
| Interventions | Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin |
| Enrollment | 100 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Apr 20, 2007 |
| Last update posted | Aug 1, 2013 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: